Background. Significant debate continues over the efficacy of drotrecogin alpha activated (DAA) in sepsis. This updated meta-analysis provides an updated summary effect estimate and explores the reasons for outcome heterogeneity in placebo-controlled randomized clinical trials of DAA on 28-day all-cause mortality in patients with severe sepsis or septic shock. Methods. Computer searches of MEDLINE, EMBASE, the Cochrane Library, ClinicalTrials.gov, published abstracts from major intensive care meetings and examination of reference lists were used to identify five placebo-controlled randomized clinical trials with 7260 patients. The primary endpoint was 28-day all-cause mortality. Secondary outcomes were 28-day incidence of severe bleeding an...
Objective: In the multinational PROWESS trial, drotrecogin alfa (activated) significantly reduced mo...
OBJECTIVE: To demonstrate that drotrecogin alfa (activated) has an acceptable safety profile 1 yr fr...
Clinical trials with novel therapeutic agents for severe sepsis have suggested that patients might r...
Background. Significant debate continues over the efficacy of drotrecogin alpha activated (DAA) in s...
Objective: To assess the effects of drotrecogin alfa (activated) therapy, a recombinant human activa...
PURPOSE: To enhance the understanding of severe sepsis, a database of patients from multiple clinica...
BACKGROUND: There have been conflicting reports on the efficacy of recombinant human activated p...
BACKGROUND: There have been conflicting reports on the efficacy of recombinant human activated prote...
Purpose: To enhance the understanding of severe sepsis, a database of patients from multiple clinica...
Objective. Sepsis is a complex inflammatory disease, rising in response to infection. Drotrecogin al...
There have been conflicting reports on the efficacy of recombinant human activated protein C, or dro...
Objective: To determine long-term survival for subjects with severe sepsis enrolled in the previous ...
Introduction Several studies have indicated that early identification and treatment of patients with...
Severe sepsis and septic shock are common in the critically ill patient and account for considerable...
The aim of our study was to evaluate the clinical impact of the administration of intravenous steroi...
Objective: In the multinational PROWESS trial, drotrecogin alfa (activated) significantly reduced mo...
OBJECTIVE: To demonstrate that drotrecogin alfa (activated) has an acceptable safety profile 1 yr fr...
Clinical trials with novel therapeutic agents for severe sepsis have suggested that patients might r...
Background. Significant debate continues over the efficacy of drotrecogin alpha activated (DAA) in s...
Objective: To assess the effects of drotrecogin alfa (activated) therapy, a recombinant human activa...
PURPOSE: To enhance the understanding of severe sepsis, a database of patients from multiple clinica...
BACKGROUND: There have been conflicting reports on the efficacy of recombinant human activated p...
BACKGROUND: There have been conflicting reports on the efficacy of recombinant human activated prote...
Purpose: To enhance the understanding of severe sepsis, a database of patients from multiple clinica...
Objective. Sepsis is a complex inflammatory disease, rising in response to infection. Drotrecogin al...
There have been conflicting reports on the efficacy of recombinant human activated protein C, or dro...
Objective: To determine long-term survival for subjects with severe sepsis enrolled in the previous ...
Introduction Several studies have indicated that early identification and treatment of patients with...
Severe sepsis and septic shock are common in the critically ill patient and account for considerable...
The aim of our study was to evaluate the clinical impact of the administration of intravenous steroi...
Objective: In the multinational PROWESS trial, drotrecogin alfa (activated) significantly reduced mo...
OBJECTIVE: To demonstrate that drotrecogin alfa (activated) has an acceptable safety profile 1 yr fr...
Clinical trials with novel therapeutic agents for severe sepsis have suggested that patients might r...